Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Alzheimer's Disease

Interventions

DRUG: AR1001
DRUG: Placebo

Sponsor

AriBio Co., Ltd.